)
Repare Therapeutics (RPTX) investor relations material
Repare Therapeutics Proxy Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Gilead Sciences agreed to acquire all assets related to the RP-3467 program, a clinical-stage polymerase theta ATPase inhibitor, from the seller for up to $30 million, including $22 million upfront, a $3 million holdback, and a $5 million transfer completion payment.
The transaction excludes other programs, employee contracts, cash, accounts receivable, real property, and equipment, focusing solely on the RP-3467 program and associated assets.
The board of directors approved the asset sale, which is expected to increase the estimated cash payment to shareholders in a pending acquisition by Xeno Therapeutics.
The asset purchase agreement includes customary representations, warranties, covenants, and indemnification provisions, with specific limitations on liability and recovery.
The transaction is not considered a merger or continuation of the seller’s business, and Gilead assumes only certain post-closing liabilities.
Voting matters and shareholder proposals
A special meeting of shareholders is scheduled for January 16, 2026, to approve the acquisition of all outstanding shares by Xeno Therapeutics.
Shareholders will vote on the proposed transaction with Xeno, with the proxy statement providing details on the arrangement and estimated per-share cash payment.
Board of directors and corporate governance
The board of directors approved the asset sale to Gilead and the arrangement agreement with Xeno Therapeutics.
Directors, executive officers, and employees may be considered participants in the proxy solicitation for the Xeno transaction.
- Shareholders to vote on XenoTherapeutics acquisition as executive transitions and compensation are detailed.RPTX
Proxy Filing - Registering up to $350M in securities to fund precision oncology R&D and corporate initiatives.RPTX
Registration Filing - Shareholders to vote on acquisition for $1.82/share plus CVR, with board unanimous support.RPTX
Proxy Filing - Shareholders to receive cash and CVRs in acquisition, with delisting and board support.RPTX
Proxy Filing - Shareholders to vote on $1.82/share cash acquisition plus CVR, with board unanimous support.RPTX
Proxy Filing - Strong efficacy and safety seen in high-risk gynecologic cancers, with pivotal trials planned.RPTX
Study Update - Promising clinical data in precision oncology set up major readouts in late 2024 and 2025.RPTX
H.C. Wainwright 26th Annual Global Investment Conference 2024 - Late Q4 data from a precision oncology trial may redefine treatment for high-risk gynecological cancers.RPTX
Morgan Stanley 22nd Annual Global Healthcare Conference - Five major clinical readouts for lunresertib and key pipeline catalysts are expected by year-end 2024.RPTX
Goldman Sachs 45th Annual Global Healthcare Conference
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)